➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Moodys
Express Scripts
Harvard Business School
Dow
Mallinckrodt

Last Updated: May 30, 2020

DrugPatentWatch Database Preview

Patent: 7,083,784

» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,083,784
Title:Molecules with extended half-lives, compositions and uses thereof
Abstract: The present invention provides molecules, including IgGs, non-IgG immunoglobulin, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.
Inventor(s): Dall\'Acqua; William (Gaithersburg, MD), Johnson; Leslie S. (Germantown, MD), Ward; Elizabeth Sally (Dallas, TX)
Assignee: MedImmune, Inc. (Gaithersburg, MD)
Application Number:10/020,354
Patent Claims:see list of patent claims

Details for Patent 7,083,784

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Medimmune SYNAGIS palivizumab VIAL 103770 002 1998-06-19   Start Trial MedImmune, Inc. (Gaithersburg, MD) 2020-12-12 RX search
Medimmune SYNAGIS palivizumab VIAL 103770 001 1998-06-19   Start Trial MedImmune, Inc. (Gaithersburg, MD) 2020-12-12 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKesson
Johnson and Johnson
Harvard Business School
Colorcon
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.